Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac voltage-dependent L-type calcium channel

Circulation Research

Volumn 108, Issue 5, 2011, Pages 607-618

  Napolitano, Carlo ^a   Antzelevitch, Charles ^b,c  

^a IRCCS   (Italy)

^b NEW YORK UNIVERSITY   (United States)

^c MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

Brugada syndrome; early repolarization syndrome; electrophysiology; Timothy syndrome; ventricular arrhythmias

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL T TYPE; CILOSTAZOL; ISOPRENALINE; MEXILETINE; QUINIDINE; RANOLAZINE; VERAPAMIL; VOLTAGE GATED CALCIUM CHANNEL;

ACTION POTENTIAL; BRUGADA SYNDROME; ELECTRIC POTENTIAL; ELECTROCARDIOGRAM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC ORGANIZATION; GENOME ANALYSIS; HEART FUNCTION; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; MOLECULAR PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TIMOTHY SYNDROME;

ARRHYTHMIAS, CARDIAC; CALCIUM CHANNELS, L-TYPE; HUMANS; MUTATION; MYOCARDIUM; PHENOTYPE;

EID: 79952743217     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.224279     Document Type: Review

References (96)

1. Colecraft HM, Alseikhan B, Takahashi SX, Chaudhuri D, Mittman S, Yegnasubramanian V, Alvania RS, Johns DC, Marban E, Yue DT. Novel functional properties of Ca(2) channel beta subunits revealed by their expression in adult rat heart cells. J Physiol. 2002;541: 435-452. (Pubitemid 35190211)
2. Chen X, Zhang X, Kubo H, Harris DM, Mills GD, Moyer J, Berretta R, Potts ST, Marsh JD, Houser SR. Ca2influx-induced sarcoplasmic reticulum Ca2overload causes mitochondrial-dependent apoptosis in ventricular myocytes. Circ Res. 2005;97:1009-1017. (Pubitemid 41668914)
3. Fatt P, Katz B. The electrical properties of crustacean muscle fibres. J Physiol. 1953;120:171-204.
4. Fleckenstein A. History of calcium antagonists. Circ Res. 1983;52(2 pt 2): I-3-I-16.
5. Mangoni ME, Traboulsie A, Leoni AL, Couette B, Marger L, Le Quang K, Kupfer E, Cohen-Solal A, Vilar J, Shin HS, Escande D, Charpentier F, Nargeot J, Lory P. Bradycardia and slowing of the atrioventricular conduction in mice lacking CaV3.1/alpha1G T-type calcium channels. Circ Res. 2006;98:1422-1430. (Pubitemid 43948067)
6. Bkaily G, Sculptoreanu A, Jacques D, Economos D, Menard D. Apamin, a highly potent fetal L-type Ca2current blocker in single heart cells. Am J Physiol. 1992;262:H463-H471.
7. Barth AS, Kuner R, Buness A, Ruschhaupt M, Merk S, Zwermann L, Kaab S, Kreuzer E, Steinbeck G, Mansmann U, Poustka A, Nabauer M, Sultmann H. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol. 2006;48:1610-1617.
8. Fournier F, Bourinet E, Nargeot J, Charnet P. Cyclic AMP-dependent regulation of P-type calcium channels expressed in Xenopus oocytes. Pflugers Arch. 1993;423:173-180. (Pubitemid 23137289)
9. Qu Y, Baroudi G, Yue Y, Boutjdir M. Novel molecular mechanism involving alpha1D (Cav1.3) L-type calcium channel in autoimmuneassociated sinus bradycardia. Circulation. 2005;111:3034-3041. (Pubitemid 40847779)
10. Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova S, Chen H, Zheng H, Striessnig J. Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2channels. Cell. 2000; 102:89-97.
11. Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, Schwartz A, Snutch TP, Tanabe T, Birnbaumer L, Tsien RW, Catterall WA. Nomenclature of voltage-gated calcium channels. Neuron. 2000;25: 533-535.
12. Tang ZZ, Liang MC, Lu S, Yu D, Yu CY, Yue DT, Soong TW. Transcript scanning reveals novel and extensive splice variations in human l-type voltage-gated calcium channel, Cav1.2 alpha1 subunit. J Biol Chem. 2004;279:44335-44343. (Pubitemid 39430838)
13. Soldatov NM, Oz M, O'Brien KA, Abernethy DR, Morad M. Molecular determinants of L-type Ca2channel inactivation. Segment exchange analysis of the carboxyl-terminal cytoplasmic motif encoded by exons 40-42 of the human alpha1C subunit gene. J Biol Chem. 1998;273: 957-963. (Pubitemid 28049191)
14. Welling A, Ludwig A, Zimmer S, Klugbauer N, Flockerzi V, Hofmann F. Alternatively spliced IS6 segments of the alpha 1C gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Ca2channels. Circ Res. 1997;81:526-532. (Pubitemid 27432739)
15. Blumenstein Y, Kanevsky N, Sahar G, Barzilai R, Ivanina T, Dascal N. A novel long N-terminal isoform of human L-type Ca2channel is up-regulated by protein kinase C. J Biol Chem. 2002;277: 3419-3423. (Pubitemid 34953211)
16. Wang D, Papp AC, Binkley PF, Johnson JA, Sadee W. Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet Genomics. 2006;16:735-745. (Pubitemid 44454868)
17. Yang Y, Chen X, Margulies K, Jeevanandam V, Pollack P, Bailey BA, Houser SR. L-type Ca2channel alpha 1c subunit isoform switching in failing human ventricular myocardium. J Mol Cell Cardiol. 2000;32: 973-984. (Pubitemid 30663105)
18. Liao P, Li G, Yu de J, Yong TF, Wang JJ, Wang J, Soong TW. Molecular alteration of Ca(v)1.2 calcium channel in chronic myocardial infarction. Pflugers Arch. 2009;458:701-711.
19. Franzini-Armstrong C, Protasi F, Ramesh V. Shape, size, and distribution of Ca(2) release units and couplons in skeletal and cardiac muscles. Biophys J. 1999;77:1528-1539.
20. Tseng GN, Boyden PA. Multiple types of Ca2currents in single canine Purkinje cells. Circ Res. 1989;65:1735-1750. (Pubitemid 20023566)
21. Abernethy DR, Soldatov NM. Structure-functional diversity of human L-type Ca2channel: perspectives for new pharmacological targets. J Pharmacol Exp Ther. 2002;300:724-728. (Pubitemid 34164972)
22. Sims C, Reisenweber S, Viswanathan PC, Choi BR, Walker WH, Salama G. Sex, age, and regional differences in L-type calcium current are important determinants of arrhythmia phenotype in rabbit hearts with drug-induced long QT type 2. Circ Res. 2008;102:e86-e100. (Pubitemid 351667868)
23. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348: 1866-1874. (Pubitemid 36532312)
24. Reichenbach H, Meister EM, Theile H. The heart-hand syndrome. A new variant of disorders of heart conduction and syndactylia including osseous changes in hands and feet. Kinderarztl Prax. 1992;60:54-56.
25. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, Tager-Flusberg H, Priori SG, Sanguinetti MC, Keating MT. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119:19-31. (Pubitemid 39349317)
26. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, Sanguinetti MC, Keating MT. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA. 2005;102:8089-8096. (Pubitemid 40800048)
27. Bloise R, Napolitano C, Timothy KW, Pontes Cavalcanti D, Szepesvary E, Drago F, Nastoli J, Splawski I, Keating MT, Priori SG. Clinical profile and risk of sudden death in children with Timothy syndrome. Circulation. 2007;114(suppl II):II-502.
28. Priori SG, Splawski I, Bloise R, Napolitano C. Timothy syndrome. In: Zipes DP, Jalife P, eds. Cardiac Electrophysiology: From Cell To Bedside. Philadelphia, PA: Elsevier. 2009;757-761.
29. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, Fan J, Kirov G, Perlis RH, Green EK, Smoller JW, Grozeva D, Stone J, Nikolov I, Chambert K, Hamshere ML, Nimgaonkar VL, Moskvina V, Thase ME, Caesar S, Sachs GS, Franklin J, Gordon-Smith K, Ardlie KG, Gabriel SB, Fraser C, Blumenstiel B, Defelice M, Breen G, Gill M, Morris DW, Elkin A, Muir WJ, McGhee KA, Williamson R, MacIntyre DJ, MacLean AW, St CD, Robinson M, Van Beck M, Pereira AC, Kandaswamy R, McQuillin A, Collier DA, Bass NJ, Young AH, Lawrence J, Ferrier IN, Anjorin A, Farmer A, Curtis D, Scolnick EM, McGuffin P, Daly MJ, Corvin AP, Holmans PA, Blackwood DH, Gurling HM, Owen MJ, Purcell SM, Sklar P, Craddock N. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008;40:1056-1058.
30. Jeon D, Kim S, Chetana M, Jo D, Ruley HE, Lin SY, Rabah D, Kinet JP, Shin HS. Observational fear learning involves affective pain system and Cav1.2 Ca2channels in ACC. Nat Neurosci. 2010;13: 482-488.
31. Silvey SV, Stoughton TL, Pearl W, Collazo WA, Belbel RJ. Rupture of the outer partition of aortic dissection during transesophageal echocardiography. Am J Cardiol. 1991;68:286-287.
32. Sansone V, Griggs RC, Meola G, Ptacek LJ, Barohn R, Iannaccone S, Bryan W, Baker N, Janas SJ, Scott W, Ririe D, Tawil R. Andersen's syndrome: a distinct periodic paralysis. Ann Neurol. 1997;42:305-312. (Pubitemid 27391113)
33. Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm. 2010;7: 549-558.
34. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP Jr, Burashnikov E, Wu Y, Sargent JD, Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haissaguerre M, Schimpf R, Borggrefe M, Wolpert C. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115: 442-449. (Pubitemid 46184195)
35. Cordeiro JM, Marieb M, Pfeiffer R, Calloe K, Burashnikov E, Antzelevitch C. Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol. 2009;46:695-703.
36. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20: 1391-1396.
37. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, Brugada P. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510-515. (Pubitemid 30080865)
38. Morita H, Morita ST, Nagase S, Banba K, Nishii N, Tani Y, Watanabe A, Nakamura K, Kusano KF, Emori T, Matsubara H, Hina K, Kita T, Ohe T. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol. 2003;42: 1624-1631. (Pubitemid 37378444)
39. Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000; 11:1320-1329. (Pubitemid 32016854)
40. Fowler SJ, Priori SG. Clinical spectrum of patients with a Brugada ECG. Curr Opin Cardiol. 2009;24:74-81.
41. Morita H, Kusano KF, Miura D, Nagase S, Nakamura K, Morita ST, Ohe T, Zipes DP, Wu J. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation. 2008;118:1697-1704.
42. Meregalli PG, Tan HL, Probst V, Koopmann TT, Tanck MW, Bhuiyan ZA, Sacher F, Kyndt F, Schott JJ, Albuisson J, Mabo P, Bezzina CR, Le Marec H, Wilde AA. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm. 2009;6:341-348.
43. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, Babuty D, Sacher F, Giustetto C, Schulze-Bahr E, Borggrefe M, Haissaguerre M, Mabo P, Le Marec H, Wolpert C, Wilde AA. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation. 2010;121:635-643.
44. Delpon E, Cordeiro JM, Nunez L, Thomsen PE, Guerchicoff A, Pollevick GD, Wu Y, Kanters JK, Larsen CT, Hofman-Bang J, Burashnikov E, Christiansen M, Antzelevitch C. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol. 2008;1:209-218.
45. Hu D, Martinez Hl, Burashnikov E, Springer M, Wu Y, Varro A, Pfeiffer K, Koopmann TT, Cordeiro JM, Guerchicoff A, Pollevick GD, Antzelevitch C. A mutation in the b3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet. 2009; 3:270-278.
46. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AA, Ackerman MJ. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009;6: 1297-1303.
47. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S, Viswanathan PC, Pfahnl AE, Shang LL, Madhusudanan M, Baty CJ, Lagana S, Aleong R, Gutmann R, Ackerman MJ, McNamara DM, Weiss R, Dudley SC Jr. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Nacurrent and causes inherited arrhythmias. Circulation. 2007;116:2260-2268. (Pubitemid 350100331)
48. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, Demolombe S, Probst V, Anselme F, Escande D, Wiesfeld AC, Pfeufer A, Kaab S, Wichmann HE, Hasdemir C, Aizawa Y, Wilde AA, Roden DM, Bezzina CR. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008;118:2260-2268. (Pubitemid 351872343)
49. Priori SG, Napolitano C, Gasparini M, Pappone C, Bella PD, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G, Nastoli J. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342-1347. (Pubitemid 34260426)
50. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O'Brien RE, Schulze-Bahr E, Keating MT, Towbin JA, Wang Q. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392:293-296. (Pubitemid 28155103)
51. Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpón E, Hu D, Desai M, Borggrefe M, Häissaguerre M, Kanter R, Pollevick GD, Guerchicoff A, Laiño R, Marieb M, Nademanee K, Nam GB, Robles R, Schimpf R, Stapleton DD, Viskin S, Winters S, Wolpert C, Zimmern S, Veltmann C, Antzelevitch C. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm. 2010;7:1872-1882.
52. Wasserburger RH, Alt WJ. The normal RS-T segment elevation variant. Am J Cardiol. 1961;8:184-192.
53. Mehta MC, Jain AC. Early repolarization on scalar electrocardiogram. Am J Med Sci. 1995;309:305-311.
54. Gussak I, Antzelevitch C. Early repolarization syndrome: clinical characteristics and possible cellular and ionic mechanisms. J Electrocardiol. 2000;33:299-309.
55. Sinner MF, Reinhard W, Muller M, Beckmann BM, Martens E, Perz S, Pfeufer A, Winogradow J, Stark K, Meisinger C, Wichmann HE, Peters A, Riegger GA, Steinbeck G, Hengstenberg C, Kaab S. Association of early repolarization pattern on ECG with risk of cardiac and all-cause mortality: a population-based prospective cohort study (MONICA/ KORA). PLoS Med. 2010;7:e1000314.
56. Tikkanen JT, Anttonen O, Junttila MJ, Aro AL, Kerola T, Rissanen HA, Reunanen A, Huikuri HV. Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med. 2009;361: 2529-2537.
57. Rosso R, Kogan E, Belhassen B, Rozovski U, Scheinman MM, Zeltser D, Halkin A, Steinvil A, Heller K, Glikson M, Katz A, Viskin S. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol. 2008;52:1231-1238.
58. Nam GB, Kim YH, Antzelevitch C. Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med. 2008;358:2078-2079. (Pubitemid 351656483)
59. Haissaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, de Roy L, Pasquie JL, Nogami A, Babuty D, Yli-Mayry S, De Chillou C, Scanu P, Mabo P, Matsuo S, Probst V, Le Scouarnec S, Defaye P, Schlaepfer J, Rostock T, Lacroix D, Lamaison D, Lavergne T, Aizawa Y, Englund A, Anselme F, O'Neill M, Hocini M, Lim KT, Knecht S, Veenhuyzen GD, Bordachar P, Chauvin M, Jais P, Coureau G, Chene G, Klein GJ, Clementy J. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008;358:2016-2023. (Pubitemid 351681636)
60. Nam GB, Ko KH, Kim J, Park KM, Rhee KS, Choi KJ, Kim YH, Antzelevitch C. Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J. 2010; 31:330-339.
61. Haissaguerre M, Chatel S, Sacher F, Weerasooriya R, Probst V, Loussouarn G, Horlitz M, Liersch R, Schulze-Bahr E, Wilde A, Kaab S, Koster J, Rudy Y, Le Marec H, Schott JJ. Ventricular fibrillation with prominent early repolarization associated with a rare variant of KCNJ8/KATP channel. J Cardiovasc Electrophysiol. 2009;20:93-98.
62. Medeiros-Domingo A, Tan BH, Crotti L, Tester DJ, Eckhardt L, Cuoretti A, Kroboth SL, Song C, Zhou Q, Kopp D, Schwartz PJ, Makielski JC, Ackerman MJ. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm. 2010;7:1466-1471.
63. Kobrinsky E, Tiwari S, Maltsev VA, Harry JB, Lakatta E, Abernethy DR, Soldatov NM. Differential role of the alpha1C subunit tails in regulation of the Cav1.2 channel by membrane potential, beta subunits, and Ca2ions. J Biol Chem. 2005;280:12474-12485.
64. Kobrinsky E, Schwartz E, Abernethy DR, Soldatov NM. Voltage-gated mobility of the Ca2channel cytoplasmic tails and its regulatory role. J Biol Chem. 2003;278:5021-5028. (Pubitemid 36801011)
65. Schroder E, Byse M, Satin J. L-type calcium channel C terminus autoregulates transcription. Circ Res. 2009;104:1373-1381.
66. Hulme JT, Yarov-Yarovoy V, Lin TW, Scheuer T, Catterall WA. Autoinhibitory control of the CaV1.2 channel by its proteolytically processed distal C-terminal domain. J Physiol. 2006;576:87-102. (Pubitemid 44426223)
67. Navedo MF, Cheng EP, Yuan C, Votaw S, Molkentin JD, Scott JD, Santana LF. Increased coupled gating of L-type Ca2channels during hypertension and Timothy syndrome. Circ Res. 2010;106:748-756.
68. Barrett CF, Tsien RW. The Timothy syndrome mutation differentially affects voltage-and calcium-dependent inactivation of CaV1.2 L-type calcium channels. Proc Natl Acad Sci USA. 2008;105:2157-2162. (Pubitemid 351439481)
69. Thiel WH, Chen B, Hund TJ, Koval OM, Purohit A, Song LS, Mohler PJ, Anderson ME. Proarrhythmic defects in Timothy syndrome require calmodulin kinase II. Circulation. 2008;118:2225-2234.
70. Sicouri S, Moro S, Litovsky S, Elizari MV, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 1997;8:1269-1279. (Pubitemid 27490695)
71. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res. 1988;62: 116-126. (Pubitemid 18032082)
72. Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation. 1996;93:372-379. (Pubitemid 26031498)
73. Antzelevitch C, Yan GX. Cellular and ionic mechanisms responsible for the Brugada syndrome. J Electrocardiol. 2000;33(Suppl):33-39. (Pubitemid 32167281)
74. Yan GX, Lankipalli RS, Burke JF, Musco S, Kowey PR. Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. J Am Coll Cardiol. 2003;42:401-409. (Pubitemid 36951702)
75. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100:1660-1666. (Pubitemid 29477277)
76. Di Diego JM, Sun ZQ, Antzelevitch C. I(to) and action potential notch are smaller in left vs. right canine ventricular epicardium. Am J Physiol. 1996;271:H548-H561.
77. Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation. 1993;87:562-572. (Pubitemid 23040926)
78. Morrissey A, Rosner E, Lanning J, Parachuru L, Dhar Chowdhury P, Han S, Lopez G, Tong X, Yoshida H, Nakamura TY, Artman M, Giblin JP, Tinker A, Coetzee WA. Immunolocalization of KATP channel subunits in mouse and rat cardiac myocytes and the coronary vasculature. BMC Physiol. 2005;5:1.
79. Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol. 2006; 29:1130-1159. (Pubitemid 44581402)
80. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341-1344. (Pubitemid 39223225)
81. Shah DP, Baez-Escudero JL, Beshai JF, Burke MC. Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8). Pacing Clin Electrophysiol. 2010 Sep 30 [Epub ahead of print].
82. Sicouri S, Timothy KW, Zygmunt AC, Glass A, Goodrow RJ, Bellardinelli L, Antzelevitch C. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazin. Heart Rhythm. 2007;4:638-647. (Pubitemid 46630371)
83. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada syndrome. Report of the Second Consensus Conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111: 659-670.
84. Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. J Electrocardiol. 2000;33(Suppl):41-47. (Pubitemid 32167282)
85. Brugada P, Brugada R, Brugada J, Geelen P. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am J Cardiol. 1999;83:98D-100D. (Pubitemid 29125688)
86. Antzelevitch C, Brugada P, Brugada J, Brugada R, Nadamanee K, Towbin JA. The Brugada syndrome. In: Clinical Approaches to Tachyarrhythmias. Armonk, NY: Futura Publishing; 1999.
87. Alings M, Dekker L, Sadee A, Wilde A. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol. 2001;24:1420-1422. (Pubitemid 32881972)
88. Belhassen B, Viskin S. Pharmacologic approach to therapy of Brugada syndrome: quinidine as alternative to ICD therapy? In: Antzelevitch C, Brugada P, Brugada J, Brugada R, eds. The Brugada Syndrome From Bench to Bedside. Oxford, UK: Wiley-Blackwell; 2004:202-211.
89. Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol. 2002;25:1634-1640. (Pubitemid 35398927)
90. Viskin S, Wilde AA, Tan HL, Antzelevitch C, Shimizu W, Belhassen B. Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm. 2009;6:401-404.
91. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol. 2001;12:268-272. (Pubitemid 32171521)
92. Tsuchiya T, Ashikaga K, Honda T, Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2002; 13:698-701. (Pubitemid 34774909)
93. Shimizu W, Matsuo K, Takagi M, Tanabe Y, Aiba T, Taguchi A, Suyama K, Kurita T, Aihara N, Kamakura S. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol. 2000;11:396-404. (Pubitemid 30215265)
94. Suzuki H, Torigoe K, Numata O, Yazaki S. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol. 2000;11: 1277-1280.
95. Tanaka H, Kinoshita O, Uchikawa S, Kasai H, Nakamura M, Izawa A, Yokoseki O, Kitabayashi H, Takahashi W, Yazaki Y, Watanabe N, Imamura H, Kubo K. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin Electrophysiol. 2001;24:1293-1294. (Pubitemid 32756933)
96. Haissaguerre M, Sacher F, Nogami A, Komiya N, Bernard A, Probst V, Yli-Mayry S, Defaye P, Aizawa Y, Frank R, Mantovan R, Cappato R, Wolpert C, Leenhardt A, de Roy L, Heidbuchel H, Deisenhofer I, Arentz T, Pasquie JL, Weerasooriya R, Hocini M, Jais P, Derval N, Bordachar P, Clementy J. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol. 2009;53:612-619.